Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
780
Trial Sponsor
Clinical Trial Start Date
November 5, 2024
0Primary Completion Date
August 5, 2025
0Study Completion Date
August 5, 2025
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Interventional Trial Phase
Phase 10
Official Name
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-AGT01 RVR in Adult Healthy Volunteers0
Last Updated
November 5, 2024
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Triple0
Masked Party
Investigator0
Care Provider0
Participant0
Other attributes
Intervention Treatment
ALN-AGT01 RVR0
Placebo0
Study summary
The purpose of this study is to evaluate the safety, tolerability and PK of single ascending doses of ALN-AGT01 RVR.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
